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Background: Asthma causes significant morbidity worldwide in adults and children alike, and incurs large
healthcare costs. The statin drugs, which treat hyperlipidemia and cardiovascular diseases, have pleiotropic effects
beyond lowering cholesterol, including immunomodulatory, anti-inflammatory, and anti-fibrotic properties which
may benefit lung health. Using an allergic mouse model of asthma, we previously demonstrated a benefit of statins
in reducing peribronchiolar eosinophilic inflammation, airway hyperreactivity, goblet cell hyperplasia, and lung IL-4
and IL-13 production.
Objectives: In this study, we evaluated whether simvastatin inhibits IL-13-induced pro-inflammatory gene
expression of asthma-related cytokines in well-differentiated primary mouse tracheal epithelial (MTE) cell cultures.
We hypothesized that simvastatin reduces the expression of IL-13-inducible genes in MTE cells.
Methods: We harvested tracheal epithelial cells from naïve BALB/c mice, grew them under air-liquid interface (ALI)
cell culture conditions, then assessed IL-13-induced gene expression in MTE cells using a quantitative real-time PCR
mouse gene array kit.
Results: We found that simvastatin had differential effects on IL-13-mediated gene expression (inhibited eotaxin-1;
MCP-1,-2,-3; and osteopontin (SPP1), while it induced caspase-1 and CCL20 (MIP-3α)) in MTE cells. For other asthma-
relevant genes such as TNF, IL-4, IL-10, CCL12 (MCP-5), CCL5 (RANTES), and CCR3, there were no significant IL-13-
inducible or statin effects on gene expression.
Conclusions: Simvastatin modulates the gene expression of selected IL-13-inducible pro-inflammatory cytokines
and chemokines in primary mouse tracheal epithelial cells. The airway epithelium may be a viable target tissue for
the statin drugs. Further research is needed to assess the mechanisms of how statins modulate epithelial gene
expression.
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reproduction in any medium, provided the orThere is increasing evidence that some widely-available
therapies, like the statin drugs (‘statins’), may benefit
patients with asthma. The statins are widely-used chol-
esterol-lowering drugs that have revolutionized the treat-
ment of cardiovascular diseases. They inhibit the
enzyme 3-hydroxy-3-methlyglutaryl–coenzyme A (CoA)
reductase (HMGR) which converts HMG-CoA into
mevalonate (MA), the rate-limiting step of cholesterol
biosynthesis (i.e. the MA pathway). The statins also have
pleiotropic HMGR- or MA-independent effects beyond
lowering cholesterol that, at least in part, belie their. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[1,2]. Observational studies show an association between
statin use and improved lung health in asthma and
chronic obstructive pulmonary disease (COPD), e.g.
reduced decline in FEV1 and FVC, reduced exacerba-
tions, and reduced mortality in COPD [3-7] Several
small clinical trials using statins to treat asthma have
shown an anti-inflammatory effect as measured by
reduced sputum leukotriene levels and leukocyte cell
counts such as macrophages and eosinophils [8-10]. On-
going clinical trials in asthma and COPD will determine
whether statins also have meaningful clinical benefits
(www.clinicaltrials.gov). However, the underlying
mechanisms and level at which the statin benefit may
occur is complex and not fully delineated.
We previously demonstrated that simvastatin amelio-
rates allergic eosinophilic airway inflammation, decreases
IL-13 and IL-4 levels in lung lavage fluid, and improves
airway hyperreactivity (AHR) in the ovalbumin mouse
model of asthma [11]. We also showed that simvastatin
attenuates early hallmarks of airway remodeling such as
goblet cell hyperplasia, arginase expression, and arginase
enzyme activity in mouse lung [12]. Others have shown
similar results using different animal models of lung in-
flammation [13]. A small number of studies evaluating
the effects of statins on human nasal, oral, and airway
epithelial cells have been reported [14-22], however, the
models utilized and hypotheses tested are not directly
relevant to asthma. But a recent clinical trial using oral
simvastatin to treat asthma, as add-on therapy to inhaled
budesonide, showed an additive effect to the inhibition
of sputum eosinophils [9]. However, the tissue specificity
of statins in lung disease remains a question of active re-
search, and it is not clear in what lung cell type(s) do the
statins have their greatest effect. Beyond systemic effects
in vivo or in humans, this anti-inflammatory effect could
be at the level of the pulmonary endothelium, mesen-
chyme, or epithelium, if not the inflammatory cells
themselves.
To explore the role of the statins in regulating airway
epithelial pro-inflammatory responses relevant to human
allergic asthma, and to build on our prior work in the
ovalbumin mouse model, we conducted a series of
in vitro experiments using primary mouse tracheal epi-
thelial cells (as previously developed by our lab) [23,24].
We hypothesized that simvastatin inhibits the expression
of IL-13-induced cytokines and chemokines in primary
mouse tracheal epithelial cells. Our data indicate that
simvastatin has differential effects on mouse epithelial
cytokine gene expression. While it inhibited the expres-
sion of some IL-13-inducible cytokines, other genes im-
portant in inflammation and host immune responses
were induced by simvastatin independent of IL-13. Our
results suggest that during IL-13-mediated stimulation,simvastatin may suppress airway epithelial pro-inflam-
matory responses relevant to asthma pathogenesis. How-
ever, the induction of some genes by simvastatin is an
interesting finding that will require exploration, as this
could have important therapeutic implications for airway
diseases given that a large segment of the human popu-
lation takes statins.
Methods
Mouse tracheal epithelial cells
All mice were housed in 24-hr dark/light conditions
breathing filtered air in our mouse vivarium facility at
U.C. Davis. Our protocol was approved by the IACUC
and monitored by on-campus veterinary scientists. With
some modifications of the procedure as described in
You et al and Robinson et al, we harvested primary
mouse tracheal epithelial (MTE) cells from naïve Balb/c
mice under sterile conditions [23,25]. Briefly, mice were
sacrificed by overdose using pentobarbital, then dipped
whole body (while sparing the mouth and nares) in
ethanol to sterilize, followed by careful blunt dissection
and removal of their lungs and tracheas. Polyethylene
(PE) tubing (0.86 mm diameter) was inserted into the
trachea and secured with sterile sutures. The trachea
was then rinsed using D-media. Enzymatic digestion
was used to remove cells from the tracheal lumen by
injecting seven drops of D-media + 0.2% Pronase Mix
into the trachea, followed by suture closure and briefly
heating the end of the PE tubing to seal it. Tracheas
were then placed in D-media and stored overnight at 4°
C. Collagen matrix coating of transwells was made of
80% collagen (PureCol™, Inamed Biomaterials, Fremont,
CA), 13.3% 1:1 F12 and DMEM, and 6.7% 0.2 M NaOH.
At least 300 μL of collagen mix was used to thoroughly
cover each transwell, and allowed to solidify over 1–
2 hrs at 37°C. Tracheal epithelial cells were then isolated
and cultured as follows: the PE tubing was cut off, 5 mL
of media was passed through each trachea and pooled
into 50 mL conical tubes (30 mL per conical tube). Cells
were centrifuged at 1,000 rpm for 15 minutes, then
supernatant removed to 5 mL, and pellet resuspended.
For multiple tracheas, tubes were combined together
and re-centrifuged for 10 minutes, then the supernatant
was removed to the 5 mL volume. The cell suspension
was corrected to a volume of 10 mL in D-media + 100
nM retinoic acid (RA). Cell suspensions (300 μL) were
then evenly distributed into each 12-well transwell, then
1 mL D-media + RA was added to each of the lower
wells in complete immersion. Tracheal epithelial cells
were then allowed to adhere to the collagen matrix for
4 days. After 2 weeks, cells were removed from immersion
culture and switched to C-media +RA (in biphasic, air-
liquid interface (ALI) cell culture conditions) with 100 μL
on top and 1 mL on bottom. Tracheal cells were then
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fluence was achieved. Two experiments were conducted
successfully, and three SA Biosciences PCR array plates
were used of which only two had reliable data.
All mouse primary tracheal epithelial cells grown in
ALI were pre-treated with simvastatin (Sim, 10 μM) for
24 hrs, then stimulated with IL-13 (20 ng/mL) and co-
incubated with Sim for 48 hrs (total Sim exposure of
72 hrs). Experiments were carried out under these drug
and cytokine concentrations unless specified otherwise
in the text.
Drugs and reagents
Simvastatin (Sim) was purchased as a pure powder from
Sigma-Aldrich (St. Louis, MO) and prepared as a stock
solution in dimethyl sulfoxide (DMSO), then diluted to
10 μM Sim using sterile 1X PBS and/or cell culture
media. Control groups of DMSO-only treatment done
previously showed no effect on measured gene expres-
sion. The final concentration of DMSO used to dissolve
Sim was 1:1,000 or 1:5,000 dilution using a Sim stock so-
lution of 10 mM or 50 mM, respectively. Simvastatin
was stored at −20°C and slowly heated to 37°C in a water
bath before applying to cells.
Cytokines
Interleukin-13 (IL-13) was purchased from R&D Sys-
tems and reconstituted using sterile 1X PBS or water,
and stored at 4°C when not in use. IL-13 was then
diluted to the appropriate dose using the cell culture
medium described above and slowly heated to 37°C in a
water bath before applying to cells.
RT-PCR gene array for mouse primary tracheal epithelial
cells
The PAMM-011E-4, RT [2] Profiler™ PCR Array kit for
mouse inflammatory cytokines and receptors was pur-
chased from SA Biosciences (Frederick, MD, USA). Fol-
lowing the manufacturer’s instructions, we used the
housekeeping gene Hsp90ab1 because this had the most
consistent level of expression across the four different
treatment groups, with the least variability in Ct values
or level of expression, when compared to other mouse
housekeeping genes including GAPDH, β-Actin, Gusb,
and Hprt1. Total RNA was extracted from primary MTE
cells after simvastatin treatment using RNA TRIzol re-
agent (Invitrogen, Carlsbad, CA) according to the manu-
facturer’s protocol. Two micrograms of extracted RNA
was converted to cDNA by adding MMLV-reverse
transcriptase (Promega, Madison, WI), 5X buffer,
dNTP, and oligo-dT primers in a total volume of 20
μL. The reaction was further diluted 1:5 to a total
volume of 100 μL with nuclease-free water and used
for real-time PCR analysis. After adding cDNAsamples to the pre-coated array plates, the RT-PCR
reaction was carried out in a 384-well optical PCR
plate according to the manufacturer’s instructions.
Results were analyzed by the ABIPRISM 7900HT Se-
quence Detection system (Applied Biosystems). The
relative amount of mRNA in each sample was calcu-
lated by normalizing its threshold cycle (Ct) value to
the Ct value of the housekeeping gene Hsp90ab1. The
calculation formula used: 2 – [GOI(Ct) - Hsp90ab1(Ct)] in
arbitrary units, where GOI stands for “gene of inter-
est.” Results are presented as gene expression relative
to the housekeeping gene Hsp90ab1.
Statistical analyses
The data are expressed as mean ± SEM. Group differ-
ences for parametric continuous data were assessed by
Student’s t-test or 1-way ANOVA with Tukey’s correc-
tion for multiple comparisons using the Prism 5 soft-
ware package (Graphpad, Inc., San Diego, CA).
Differences were considered to be statistically significant
for a 2-way alpha and p-value ≤ 0.05.
Results
Simvastatin inhibits the expression of pro-inflammatory
cytokines in mouse tracheal epithelial cells
We explored whether simvastatin (10 μM) inhibits IL-
13-induced pro-inflammatory cytokine/chemokine gene
expression using a RT-PCR gene array. Treatment with
Sim reduced eotaxin-1 (CCL11) expression by 87.8%
(*p< 0.0001 by ANOVA) (Figure 1). Simvastatin also
inhibited the expression of eotaxin-2 (CCL24) in mouse
airway epithelial cells by 50.2% but this did not reach
statistical significance (p =NS by ANOVA or t-test, data
not shown). Simvastatin also reduced IL-13-induced
MCP-1 (CCL2) expression by 84.0% (*p< 0.005 for con-
trol vs. IL-13, and **p< 0.005 for IL-13 vs. IL-13 + Sim;
by ANOVA, Figure 2A). Simvastatin reduced IL-13
-induced MCP-2 (CCL8) expression by 53.7% (*p< 0.05
for control vs. IL-13, and p =NS for IL-13 vs.
IL- 13 + Sim by ANOVA or t-test, Figure 2B). Simvasta-
tin reduced IL-13-induced MCP-3 (CCL7) expression by
87.2% (*p< 0.05 for control vs. IL-13, and **p< 0.05 for
IL-13 vs. IL-13 + Sim; by ANOVA, Figure 2C).
The mouse genes for which there was either insuffi-
cient IL-13 stimulation and/or lack of statistically signifi-
cant inhibition of gene expression by simvastatin include
the following (data not shown): TNFβ, TNF, CCL9
(MIP-1γ), IL-1β, IL-4, IL-13, IL-10, IL-11, IL-15, IL-17B,
CRP, CCL12 (MCP-5), CCL19 (MIP-3β), CCL5
(RANTES), CXCL1 (Gro-α), CXCL5, CXCL10 (IP-10),
CXCL11, CXCL12 (SDF), C3, ABCF1, CCR1, CCR3-6,
CCR8, CCR9, CXCL9, and IL-5Ra. Simvastatin also
inhibited the expression of IL-13-induced TGFβ expres-
sion by 80.1% but this was not statistically significant
Figure 2 Simvastatin inhibits Monocyte Chemotactic Protein (MCP) ge
primary tracheal epithelial cells grown in air-liquid interface (ALI) were pre-
IL-13 (20 ng/mL) and co-incubated with Sim for 48 hrs (total Sim exposure
IL-13-induced MCP-1 (CCL2) expression by 84.0% (*p< 0.005 for control vs.
Simvastatin treatment had no statistically significant inhibition of basal MCP
reduced IL-13-induced MCP-2 (CCL8) expression by 53.7% (*p< 0.05 for co
Simvastatin treatment did not inhibit the basal expression of MCP-2 (Con. v
MCP-3 (CCL7) expression by 87.2% (*p< 0.05 for control vs. IL-13, and **p<
did not inhibit the basal expression of MCP-3 (Con. versus Sim 10 μM; p=N
Figure 1 Simvastatin inhibits Eotaxin-1 expression in mouse
primary tracheal epithelial cells. Mouse primary tracheal epithelial
cells grown in air-liquid interface (ALI) were pre-treated with
simvastatin (Sim, 10 μM) for 24 hrs, then stimulated with IL-13
(20 ng/mL) and co-incubated with Sim for 48 hrs (total Sim
exposure of 72 hrs). Gene expression was evaluated by RT-PCR.
Treatment with Sim reduced eotaxin-1 (CCL11) expression by 87.8%
(*p< 0.0001 by ANOVA). Simvastatin treatment had no statistically
significant effect on basal expression of eotaxin-1 (Con. versus Sim
10 μM; p =NS by ANOVA).
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portant to note that IL-13 is not known to induce some
of these aforementioned cytokines/chemokines given dif-
ferent cell signaling pathways, and this may also reflect
the lack of induction or clear differences with statin
treatment.
One component of the IL-6 receptor is the IL-6 signal
transducer (IL-6st) protein (a.k.a. Glycoprotein 130),
which is important for signal transduction following
cytokine engagement of the receptor. Treatment with
Sim inhibited the IL-13-induced expression of IL-6st
gene by 54% (p =NS by ANOVA, but *p = 0.039 by t-test,
data not shown).
In our evaluation of primary MTE cells, one gene in
particular displayed significant inhibition with simvasta-
tin, the pro-inflammatory and pleiotropic cytokine
osteopontin or SPP1 (secreted phosphoprotein 1). In the
control group, Sim inhibited the expression of osteopon-
tin by 95.5% (*p< 0.05 by ANOVA) independent of
IL-13 stimulation, and in the IL-13 group Sim decreased
osteopontin expression by 93.6% (**p< 0.05 by ANOVA)
(Figure 3).
Simvastatin induces the expression of genes in mouse
tracheal epithelial cells
Simvastatin treatment induced the expression of a mi-
nority of genes as detected in our PCR array analysis.
For the limited collection of genes we evaluated, we
observed the induction of CCL20 (MIP-3α) and caspase-
1 expression by simvastatin. Exposure to IL-13 did notne expression in mouse primary tracheal epithelial cells. Mouse
treated with simvastatin (Sim, 10 μM) for 24 hrs, then stimulated with
of 72 hrs). Gene expression was evaluated by RT-PCR. (A) Sim reduced
IL-13, and **p< 0.005 for IL-13 vs. IL-13 + Sim; both by ANOVA).
-1 expression (Con. versus Sim 10 μM; p =NS by ANOVA). (B) Sim
ntrol vs. IL-13, and p=NS for IL-13 vs. IL-13 + Sim by ANOVA or t-test).
ersus Sim 10 μM; p =NS by ANOVA). (C) Sim reduced IL-13-induced
0.05 for IL-13 vs. IL-13 + Sim; both by ANOVA). Simvastatin treatment
S by ANOVA).
Figure 3 Simvastatin inhibits the expression of Osteopontin
(SPP1) in mouse primary tracheal epithelial cells. Mouse primary
tracheal epithelial cells grown in air-liquid interface (ALI) were pre-
treated with simvastatin (Sim, 10 μM) for 24 hrs, then stimulated
with IL-13 (20 ng/mL) and co-incubated with Sim for 48 hrs (total
Sim exposure of 72 hrs). Gene expression was measured by RT-PCR.
In the control group, Sim inhibited the expression of osteopontin by
95.5% (*p< 0.05 by ANOVA) independent of IL-13 stimulation, and
in the IL-13 group Sim decreased osteopontin expression by 93.6%
(**p< 0.05 by ANOVA).
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simvastatin induced caspase-1 expression by 285% in the
control group (*p< 0.005 by ANOVA) and by 310% in
the IL-13 group (**p< 0.005 by ANOVA) (Figure 4A).
Also, IL-13 did not induce CCL20 expression, however,Figure 4 Simvastatin induces the expression of CCL20 (MIP-3α) and C
tracheal epithelial cells grown in air-liquid interface (ALI) were pre-treated w
(20 ng/mL) and co-incubated with Sim for 48 hrs (total Sim exposure of 72
induce caspase-1 expression. Treatment with simvastatin induced caspase-1
by 310% in the IL-13 group (**p< 0.005 by ANOVA). (B) IL-13 did not indu
expression by 451% in the control group (p =NS by ANOVA or t-test) andtreatment with simvastatin induced CCL20 expression
by 451% in the control group (p =NS by ANOVA or
t-test)and by 441% in the IL-13 group (#p =NS by
ANOVA, but p = 0.011 by t-test) (Figure 4B).
For all of the data reported, in two separate experiments
we did not observe any qualitative or visual evidence of
cell morphological changes, gross signs of cytotoxicity, or
overt cell death with simvastatin treatment.Discussion
We and others previously showed that systemic treat-
ment of mice with simvastatin attenuates allergic inflam-
mation, decreases the production of Th2 cytokines IL-4
and IL-13, reduces goblet cell hyperplasia, and improves
AHR [11,12,26,27]. Collectively, these results suggested
both an anti-inflammatory and epithelial anti-
remodeling effect of simvastatin in vivo [11,12,28]. Given
the central role of the airway epithelium in asthma
pathogenesis [29,30], we wanted to determine the effect
of simvastatin on genes known to play a role in allergic
airway inflammation using primary MTE cells. We fo-
cused on IL-13-responsive genes given (a) our prior
in vivo observations showing marked simvastatin inhib-
ition of IL-13 production in mouse lung lavage fluid
[11], and (b) its importance in human asthma and aller-
gic inflammation. Our primary findings are that in vitro
treatment with simvastatin (1) decreased the expression
of IL-13-induced genes such as eotaxin-1 and the
MCPs, while (2) it enhanced the basal expression of cer-
tain IL-13 non-inducible genes. To our knowledge, this
is the first paper that evaluates the effect of simvastatin
on IL-13-induced pro-inflammatory gene expression in
primary MTE cells using an ALI system, consistent withaspase-1 in mouse primary tracheal epithelial cells. Mouse primary
ith simvastatin (Sim, 10 μM) for 24 hrs, then stimulated with IL-13
hrs). Gene expression was evaluated by RT-PCR. (A) IL-13 did not
expression by 285% in the control group (*p< 0.005 by ANOVA) and
ce CCL20 expression. Treatment with simvastatin induced CCL20
by 441% in the IL-13 group (#p =NS by ANOVA, but p = 0.011 by t-test).
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inflammatory pathways pertinent to eosinophilic allergic
inflammation in vivo [11].
Our data show significant inhibition of IL-13-inducible
CCL class cytokines eotaxin-1, and MCP-1,-2, and −3 by
simvastatin (Figures 1 and 2). These cytokines are im-
portant eosinophil chemoattractants relevant to human
allergic asthma. Eotaxins are potent eosinophil tissue
chemoattractants, and the MCPs inhibit IL-12 and in-
crease IL-4 production leading to enhanced Th2
responses, and monocyte, basophil, and eosinophil re-
cruitment. Pertinent to our findings, there is emerging
clinical evidence that simvastatin can reduce sputum eo-
sinophil counts. A recent clinical study in asthmatics
showed that simvastatin 10 mg (taken orally) plus
inhaled budesonide resulted in a significant reduction in
sputum eosinophils when compared to the budesonide
control group (10.0% reduction vs. 6.75% reduction, p
< 0.02 for %eosinophils) [9]. Although our current data
are derived from in vitro experiments, it is plausible that
simvastatin’s in vivo anti-inflammatory effects may also
be due to suppression of cytokine gene expression in the
airway epithelium resulting in reduced eotaxin produc-
tion, and hence, reduced eosinophil tissue trafficking
into airways. Candidate downstream targets of the statin
effect include both the sterol and isoprenoid (non-sterol)
branch pathways, i.e. cholesterol vs. Rho/Ras/Rac
GTPase signaling in the MA pathway. Further work is
needed to better characterize the mechanism(s) involved
in the regulation of gene expression by statins in the air-
way epithelium.
In addition to inhibiting these important multifunc-
tional Th2 cytokines, simvastatin also inhibited the basal
gene expression of osteopontin (a.k.a. SPP1) independ-
ent of IL-13 (Figure 3). Osteopontin is an integrin lig-
and and a cytokine with a variety of actions important
in asthma pathogenesis, including stimulating macro-
phages, recruiting neutrophils and Th1 cells, and pro-
moting anti-apoptotic pathways [31]. It also induces
airway mucin production and has an emerging role in
the pathogenesis of both asthma and COPD [32-35].
There is significant interest in the role of osteopontin
in asthma pathogenesis where Simoes and colleagues
recently showed that ovalbumin-exposed mice lacking
the osteopontin gene did not develop airway hyperre-
sponsivness or remodeling [36]. Prior studies showed
that osteopontin is produced by a variety of cells in-
cluding bone, smooth muscle, epithelial, T lymphocyte,
and dendritic cells [37]. Our results provide evidence
that it is expressed by mouse tracheal epithelium and is
either a marker of allergic inflammation or is a critical
cytokine in disease pathogenesis. This adds to the
evidence that simvastatin inhibits important pro-
inflammatory cytokines relevant to airway diseases,especially the contribution of the airway epithelium to
allergic Th2 inflammation.
Unexpectedly, simvastatin also induced the expression
of CCL20 (MIP-3α) and caspase-1 (Figure 4), independ-
ent of IL-13. Although CCL20 is a pro-inflammatory
cytokine that attracts natural killer (NK) cells and mem-
ory T-cells to sites of inflammation, this peptide also
retains potent antimicrobial effects even greater than
HBD-2 [38,39]. Caspase-1 is known for its activation of
apoptosis and pro-inflammatory regulation of IL-1β
[40,41], however, it may also mediate lung healing pro-
cesses via IL-1β [41] and critical host defense mechan-
isms that prevent infections [40]. Given the pleiotropic
effects of CCL20 and caspase-1 [42] it is unclear
whether the induction of these genes by simvastatin
would have a beneficial or harmful effect overall. This
would dependent on the context of the intact/physio-
logic airway compartment; the presence of exogenous
stimulants, the microbial environment, presence of in-
fection, and overall immune milieu. However, we know
from multiple studies using different animal models of
lung inflammation, that systemic treatment with statins
attenuates lung and peri-bronchiolar inflammation,
reduces epithelial mucus production, and improves AHR
suggesting that the sum effect in the intact host is likely
beneficial [11,27,43-45].
It is well-accepted that the cytokine milieu in asthma is
rather complex and involves, amongst many different im-
mune cell types, T-cell-mediated mechanisms such as Th1,
Th2, Th17 and regulatory Treg pathways [46].
Interleukin-1β, CXCL10 (IP-10), and TNF are all Th1
polarized cytokines that play a role in the pathogenesis of
asthma [46-48]. However, unlike CCL20 (MIP-3α) and
caspase-1, simvastatin treatment did not inhibit or induce
these important cytokines. Thus, our data do not support
a statin effect on the basal gene expression of IL-1β,
CXCL10 (IP-10), or TNF. Besides inhibition of eotaxin-1
and MCP expression by simvastatin, neither IL-13 nor
simvastatin treatment changed the expression of other
asthma-relevant Th2-type cytokines such as IL-4, CCL5
(RANTES), CCR3, or IL-5Ra. Given the central role these
cytokines/chemokines and receptors play in eosinophilic
trafficking, we speculate that the potent anti-eosinophilic
effect of simvastatin seen previously in animal models
[11,26] may not be due to epithelial effects alone, but
might involve the vascular compartment or other airway
resident cells that participate in eosinophil recruitment.
There were no statistically significant IL-13- or simvatatin-
mediated effects on Th1/Th2 cytokines CCL12 (MCP-5)
and TGFβ, or on the Treg cytokine IL-10; all important
players in asthmatic inflammation [46]. However, there
was a trend of TGFβ inhibition by simvastatin, and given
the role this cytokine plays in asthma, further research
may reveal an important statin effect in epithelial cells.
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IL-13-inducible pro-inflammatory genes pertinent to
asthma, however, it also unexpectedly induced the ex-
pression of some genes potentially relevant to inflamma-
tion, immune function, and cell survival. Whether
statins affect gene expression at the transcriptional or
post-transcriptional level in airway epithelial cells, and
the mechanisms involved, remains to be determined. We
believe it is important to report these statin effects on
murine airway epithelial cells in order to refine future
work in this field, at least as relevant to mouse models
that utilize the airway epithelium. Furthermore, this
in vitro ALI/biphasic model is an efficient and experi-
mentally accessible cell culture system that mimics
‘near-physiological’ conditions and encourages the test-
ing of a wider range of statin doses on airway epithelial
function in general [49,50]. This facilitates the direct
study of statins’ molecular mechanisms of action, as
compared to less direct animal models with the attend-
ant complexities of the in vivo environment.
We also chose the MTE cell culture system because it
is a natural extension of our prior work in the ovalbumin
allergic mouse model. We wanted to know the relative
contribution of the murine epithelium to allergic airway
inflammation, and whether simvastatin has direct benefi-
cial effects on this key constituent of the airway. The
MTE system allowed us to study the statin effect in isola-
tion without the numerous cell-cell interactions that can
limit data interpretation and the complex influence of
leukocyte-epithelial interactions that happen in vivo.
What we learn from MTE cells can be applied to ongoing
studies using human airway epithelial cells, as knowledge
gained from one approach will inform the other.
We are not aware of any studies which evaluate the ef-
fect of statins on airway epithelial gene expression using
microchip arrays. This study is a small step in that direc-
tion and gives a broader picture of which airway epithe-
lial genes are up- and down-regulated by statins.
However, given that we do not know the full spectrum
of the statin effect on airway epithelial cell function, add-
itional studies aimed at uncovering the physiological
consequences and signaling pathways involved are war-
ranted. At the dose and treatment duration examined in
our study, simvatatin clearly has differential effects on
pro-inflammatory epithelial gene expression. Thus, add-
itional dose- and time-response studies, and the screen-
ing of both hydrophilic and hydrophobic statins, may
shed light on the spectrum of statin effects on epithelial
gene expression. Furthermore, whether or not simvasta-
tin’s effects on cytokine gene expression involves HMGR
inhibition, the canonical target of the statin drugs in the
MA pathway, is a hypothesis worth testing.
Whether or not our findings can be extrapolated to
human airway epithelial cells is not entirely clear.However, the basic mechanisms related to mevalonate
and HMGR biology are generally conserved across
eukaryotes which suggest that the statin effects should
also be similar. Although not studied directly in asth-
matic airways or under allergic conditions, the few pub-
lished papers evaluating the effects of statins on
human bronchial epithelial cells show inhibition of pro-
inflammatory cytokine/chemokine expression [15,16,21].
This leads us to believe that our results may be extrapo-
lated to human epithelial cells, although more research
is needed to further test this hypothesis and the under-
lying mechanisms of action.
There are several limitations to the work presented
here: (1) We evaluated a relatively small number of IL-
13-inducible mouse genes relevant to allergic asthma.
Indeed, the statins may be affecting a host of other genes
not evaluated in our experiments. Because the pathogen-
esis of allergic asthma is complex and polygenic, a more
complete evaluation of statins’ effects on lung gene ex-
pression is needed. (2) We did not determine the mech-
anism(s) of how simvastatin inhibits gene expression,
however, we speculate that the HMGR enzyme/MA
pathway plays an important role. (3) Because this was a
mouse in vitro study, we cannot necessarily generalize to
the in vivo situation, and extrapolation to human disease
would be premature. (4) Inhibition of gene expression in
the airway epithelium will not necessarily translate into
clinical benefits, but such findings are promising. In fu-
ture studies, evaluating human tracheobronchial epithe-
lial brush biopsies from patients taking statins could
more directly establish translational relevance.Conclusions
Our data indicate that simvastatin modulates murine air-
way epithelial inflammatory gene expression relevant to
asthma. In addition to inhibition of IL-13-inducible cyto-
kines, simvastatin also induced some genes relevant to
inflammation and host defense. The statins may have a
therapeutic role in asthma or COPD, however, more
work is needed to characterize the mechanism(s) of how
statins affect gene expression in airway epithelial cells.
Similar evaluations in human airway epithelial cells
derived from patients with asthma and COPD are neces-
sary and will guide future clinical studies.
Abbreviations
MA: Mevalonate; HMGR: HMG-CoA reductase; MCP: Monocyte chemotactic
protein; ALI: Air-liquid interface; Sim: Simvastatin; SPP1: Secreted
phosphoprotein 1; FPP: Farnesylpyrophosphate;
GGPP: Geranylgeranylpyrophosphate; COPD: Chronic obstructive pulmonary
disease; GTPase: Guanosine triphosphatase; i.p.: Intraperitoneal; NK: Natural
killer cells; FEV1: Forced expiratory volume in the first second; FVC: Forced
vital capacity; AHR: Airway hyperreactivity; PE: Polyethylene; RA: Retinoic acid;
DMSO: Dimethyl sulfoxide; Ct: Threshold cycle; GOI: Gene of interest;
SEM: Standard error of the mean; ANOVA: Analysis of variance; RT-
PCR: Quantitative real time-polymerase chain reaction; CC: Cysteine-cysteine;
Zeki et al. Respiratory Research 2012, 13:38 Page 8 of 9
http://respiratory-research.com/content/13/1/38CCL: Cysteine-cysteine ligand; NK: Natural killer; HBD-2: Human β-defensin-2;
MTE: Mouse tracheal epithelium; Treg: Regulatory T-cell.
Competing interests
The authors declare that they have no competing interests.
Acknowledgements
We thank Professor Jerold Last for his helpful discussions, and Dr. Li-Yin
Hung for assistance with harvesting mouse tracheal epithelial cells.
Funding/Support
NIH T32 HL07013 (AAZ), NCRR UL1 RR024146 (CTSC K30 Award; AAZ), HL-
076415 (NJK), American Thoracic Society (ATS) Fellows Career Development
Award (AAZ), CTSC K12 Award (AAZ), HL077902-05A1 and HL096373 (RW).
Authors’ contributions
RW and AAZ conceived of the project, and experimental design. PT helped
refine the experimental approach and assisted with RT-PCR. AAZ carried out
the tracheal harvesting, cDNA preparation, and running the RT-PCR arrays.
AAZ did the statistical analysis. NJK had significant intellectual input into the
development of this work, and added to the Discussion. All authors
reviewed data and results, and had significant input into the writing of the
final manuscript. All authors read and approved the final manuscript.
Received: 08 February 2012 Accepted: 14 May 2012
Published: 14 May 2012
References
1. Liao JK, Laufs U: Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol
2005, 45:89–118.
2. Greenwood J, Steinman L, Zamvil SS: Statin therapy and autoimmune
disease: from protein prenylation to immunomodulation. Nat Rev
Immunol 2006, 6(5):358–370.
3. Alexeeff SE, Sparrow D, Vokonas PS, Schwartz J: Statin use reduces decline
in lung function: VA Normative Aging Study. Am J Respir Crit Care Med
2007, 176:742–747.
4. Mancini GB, Zhang B, Levesque LE, FitzGerald JM, Brophy JM: Reduction of
morbidity and mortality by statins, angiotensin-converting enzyme
inhibitors, and angiotensin receptor blockers in patients with chronic
obstructive pulmonary disease. J Am Coll Cardiol 2006, 47(12):2554–2560.
5. Ishida W, Ishii M, Fujiwara F, Taneichi H, Takebe N, Takahashi K, Kaneko Y,
Segawa I, Kajiwara T, Inoue H, Satoh J: Decrease in Mortality Rate of
Chronic Obstructive Pulmonary Disease (COPD) with Statin Use: A
Population-Based Analysis in Japan. J Exp Med 2007, 212(3):265–273.
6. Young RP, Hopkins R, Eaton TE: Potential benefits of statins on morbidity
and mortality in chronic obstructive pulmonary disease: a review of the
evidence. Postgrad Med J 2009, 85(1006):414–421.
7. Blamoun AI, DeBari VA, Rashid AO, Sheikh M, Khan MA: Statins may reduce
episodes of exacerbation and the requirement for intubation in patients
with COPD: evidence from a retrospective cohort study. Int J Clin Pract
2008, 62(9):1373–1378.
8. Hothersall EJ, Chaudhuri R, McSharry C, et al: Effects of atorvastatin added
to inhaled corticosteroids on lung function and sputum cell counts in
atopic asthma. Thorax 2008, 63(12):1070–1075.
9. Maneechotesuwan K, Ekjiratrakul W, Kasetsinsombat K, Wongkajornsilp A,
Barnes PJ: Statins enhance the anti-inflammatory effects of inhaled
corticosteroids in asthmatic patients through increased induction of
indoleamine 2,3-dioxygenase. J Allergy Clin Immunol 2010, 126(4):754–762.
10. Cowan DC, Cowan JO, Palmay R, Williamson A, Taylor DR: Simvastatin in
the treatment of asthma: lack of steroid-sparing effect. Thorax 2010, 65
(10):891–896.
11. Zeki AA, Franzi L, Last J, Kenyon NJ: Simvastatin Inhibits Airway
Hyperreactivity: Implications for the Mevalonate Pathway and Beyond.
Am J Respir Crit Care Med 2009, 180:731–740.
12. Zeki AA, Bratt JM, Rabowsky M, Last JA, Kenyon NJ: Simvastatin inhibits
goblet cell hyperplasia and lung arginase in a mouse model of allergic
asthma: A novel treatment for airway remodeling? Transl Res 2010, 156
(6):335–349.
13. Ou XM, Wen FQ, Feng YL, Huang XY, Xiao J: Simvastatin attenuates
lipopolysaccharide-induced airway mucus hypersecretion in rats. Chin
Med J 2008, 121(17):1680–1687.14. Vukelic S, Stojadinovic O, Pastar I, et al: Farnesyl pyrophosphate inhibits
epithelialization and wound healing through the glucocorticoid
receptor. J Biol Chem 2010, 285(3):1980–1988.
15. Murphy DM, Corris PA, Johnson GE, Small T, Jones D, Fisher AJ, Egan JJ,
Cawston TE, Ward C, Lordan JL: Simvastatin attenuates release of
neutrophilic and remodeling factors from primary bronchial epithelial
cells derived from stable lung transplant recipients. Am J Physiol Lung Cell
Mol Physiol 2008, 294:592–599.
16. Wang W, Le W, Ahuja R, Cho DY, Hwang PH, Upadhyay D: Inhibition of
Inflammatory Mediators: Role of Statins in Airway Inflammation.
Otolaryngol Head Neck Surg 2011, 144(6):982–987.
17. Sakoda K, Yamamato M, Negishi Y, Liao JK, Node K, Izumi Y: Simvastatin
decreases IL-6 and IL-8 production in epithelial cells. J Dent Res 2006, 85
(6):520–523.
18. Wu S, Duan S, Zhao S, Cai Y, Chen P, Fang X: Atorvastatin reduces
lipopolysaccharide-induced expression of cyclooxygenase-2 in human
pulmonary epithelial cells. Respir Res 2005, 6:27.
19. Sakamoto N, Hayashi S, Mukae H, Vincent R, Hogg JC, van Eeden SF: Effect
of atorvastatin on PM10-induced cytokine production by human
alveolar macrophages and bronchial epithelial cells. Int J Toxicol 2009,
28(1):17–23.
20. Kreiselmeier NE, Kraynack NC, Corey DA, Kelley TJ: Statin-mediated
correction of STAT1 signaling and inducible nitric oxide synthase
expression in cystic fibrosis epithelial cells. Am J Physiol Lung Cell Mol
Physiol 2003, 285(6):L1286–L1295.
21. Iwata A, Shirai R, Ishii H, et al: Inhibitory Effect of Statins on Inflammatory
Cytokine Production from Human Bronchial Epithelial Cells. Clin Exp
Immunol 2012, 168(2):234–240.
22. Kraynack NC, Corey DA, Elmer HL, Kelley TJ: Mechanisms of NOS2
regulation by Rho GTPase signaling in airway epithelial cells. Am J Physiol
Lung Cell Mol Physiol 2002, 283(3):L604–L611.
23. Robinson CB, Wu R: Culture of Conducting Airway Epithelial in Serum-
Free Medium. J Tissue Cult Meth 1991, 13(20):95–102.
24. Wu R, Nolan E, Turner C: Expression of tracheal differentiated functions in
serum-free hormone-supplemented medium. J Cell Physiol 1985, 125
(2):167–181.
25. You Y, Richer EJ, Huang T, Brody SL: Growth and differentiation of mouse
tracheal epithelial cells: selection of a proliferative population. Am J
Physiol Lung Cell Mol Physiol 2002, 283(6):L1315–L1321.
26. McKay A, Leung BP, McInnes IB, Thomson NC, Liew FY: A novel anti-
inflammatory role of simvastatin in a murine model of allergic asthma.
J Immunol 2004, 172(5):2903–2908.
27. Kim DY, Ryu SY, Lim JE, Lee YS, Ro JY: Anti-inflammatory mechanism of
simvastatin in mouse allergic asthma model. Eur J Pharmacol 2007,
557:76–86.
28. Ahmad T, Mabalirajan U, Sharma A, et al: Simvastatin improves epithelial
dysfunction and airway hyperresponsiveness: from asymmetric
dimethyl-arginine to asthma. Am J Respir Cell Mol Biol 2011, 44(4):531–539.
29. Holgate ST: Epithelium dysfunction in asthma. J Allergy Clin Immunol 2007,
120:1233–1244.
30. Holgate ST: The Airway Epithelium is Central to the Pathogenesis of
Asthma. Allergol Int 2008, 57:1–10.
31. Konno S, Kurokawa M, Uede T, Nishimura M, Huang S-K: Role of
osteopontin, a multifunctional protein, in allergy and asthma. Clin Exp
Allergy Rev 2011, 41(10):1360–1366.
32. Schneider DJ, Lindsay JC, Zhou Y, Molina JG, Blackburn MR: Adenosine and
osteopontin contribute to the development of chronic obstructive
pulmonary disease. FASEB 2010, 24(1):70–80.
33. Sabo-Attwood T, Ramos-Nino ME, Eugenia-Ariza M, et al: Osteopontin
modulates inflammation, mucin production, and gene expression
signatures after inhalation of asbestos in a murine model of fibrosis. Am
J Pathol 2011, 178(5):1975–1985.
34. Samitas K, Zervas E, Vittorakis S, et al: Osteopontin expression and relation
to disease severity in human asthma. Eur Respir J 2011, 37(2):331–341.
35. Delimpoura V, Bakakos P, Tseliou E, et al: Increased levels of osteopontin in
sputum supernatant in severe refractory asthma. Thorax 2010, 65(9):782–
786.
36. Simoes DCM, Xanthou G, Petrochilou K, Panoutsakopoulou V, Roussos C,
Gratziou C: Osteopontin deficiency protects against airway remodeling
and hyperresponsiveness in chronic asthma. Am J Respir Crit Care Med
2009, 179(10):894–902.
Zeki et al. Respiratory Research 2012, 13:38 Page 9 of 9
http://respiratory-research.com/content/13/1/3837. Xanthou G, Alissafi T, Semitekolou M, et al: Osteopontin has a crucial role
in allergic airway disease through regulation of dendritic cell subsets.
Nat Med 2007, 13(5):570–578.
38. Hoover DM, Boulegue C, Yang D, Oppenheim JJ, Tucker K, Lu W, Lubkowski
J: The structure of human macrophage inflammatory protein-3a/CCL20.
Linking antimicrobial and CC chemokine receptor-6-binding activities
with human b-defensins. J Biol Chem 2002, 277(40):37647–37654.
39. Yang D: Many chemokines including CCL20/MIP-3alpha display
antimicrobial activity. J Leukoc Biol 2003, 74(3):448–455.
40. Shimada K, Crother TR, Karlin J, et al: Caspase-1 dependent IL-1β secretion
is critical for host defense in a mouse model of Chlamydia pneumoniae
lung infection. PLoS One 2011, 6(6):e21477.
41. Thomas PG, Dash P, Aldridge JR, et al: The intracellular sensor NLRP3
mediates key innate and healing responses to influenza A virus via the
regulation of caspase-1. Immunity 2009, 30(4):566–575.
42. Kumar S: Caspases and their many biological functions. Cell Death Differ
2006, 14(1):1–2.
43. Imamura M, Okunishi K, Ohtsu H, Nakagome K, Harada H, Tanaka R,
Yamamoto K, Dohi M: Pravastatin attenuates allergic airway inflammation
by suppressing antigen sensitization, interleukin 17 production and
antigen presentation in the lung. Thorax 2009, 64:44–49.
44. Fessler MB, Jeyaseelan S, Lieber JG, Arndt PG, Nick JA, Worthen GS, Young
SK: A role for hydroxy methylglutaryl coenzyme A reductase in
pulmonary inflammation and host defense. Am J Respir Crit Care Med
2005, 171(6):606–615.
45. Y-Juan C, Chen P, Wang H-Xia, et al: Simvastatin attenuates acrolein-
induced mucin production in rats: Involvement of the Ras / extracellular
signal-regulated kinase pathway. Int Immunopharmacol 2010, 10(6):
685–693.
46. Barnes PJ: The cytokine network in asthma and chronic obstructive
pulmonary disease. J Clin Invest 2008, 118(11):3546–3556.
47. Anderson GP: Endotyping asthma: new insights into key pathogenic
mechanisms in a complex, heterogeneous disease. Lancet 2008, 372
(9643):1107–1119.
48. Cho S-H, Stanciu L, Holgate ST, Johnston SL: Increased interleukin-4,
interleukin-5, and interferon-gamma in airway CD4+ and CD8+ T cells in
atopic asthma. Am J Respir Crit Care Med 2005, 171(3):224–230.
49. Dvorak A, Tilley AE, Shaykhiev R, Wang R, Crystal RG: Do airway epithelium
air-liquid cultures represent the in vivo airway epithelium transcriptome?
Am J Respir Cell Mol Biol 2011, 44(4):465–473.
50. Hirota J, Hackett T-L, Inman MD, Knight D: Modeling asthma in mice: what
have we learned about the airway epithelium? Am J Respir Cell Mol Biol
2011, 44(4):431–438.
doi:10.1186/1465-9921-13-38
Cite this article as: Zeki et al.: Differential effects of simvastatin on
IL-13-induced cytokine gene expression in primary mouse tracheal
epithelial cells. Respiratory Research 2012 13:38.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
